Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 20
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
NewAmsterdam Pharma Co NV
NAMS
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$21.50
1.03
5.03%
Dern. MÀJ: Oct 20, 5:00 PM
$21.50
1.03
5.03%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
NewAmsterdam Pharma Co Financials
NewAmsterdam Pharma Co (NAMS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
NewAmsterdam Pharma Q2 EPS $(0.52) Misses $(0.48) Estimate, Sales $3.701M Beat $1.663M Estimate
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.48) by 8.33 percent. This is a 246.67 percent decrease over losses of $(0.15) per share
Benzinga Newsdesk
PRO
NewAmsterdam Pharma Q1 EPS $(0.40) Beats $(0.47) Estimate, Sales $3.040M Beat $936.364K Estimate
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.47) by 14.89 percent. This is a 17.65 percent decrease over losses of $(0.34) per share
Benzinga Newsdesk
Earnings Summary: NewAmsterdam Pharma Co Q4
Benzinga Insights
PRO
NewAmsterdam Pharma Q3 EPS $(0.61) Misses $(0.41) Estimate, Sales $348.000K Miss $5.287M Estimate
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.41) by 47.34 percent. This is a 238.89 percent decrease over losses of $(0.18) per share
Benzinga Newsdesk
PRO
NewAmsterdam Pharma Q2 EPS $(0.15) Beats $(0.46) Estimate, Sales $19.145M Beat $2.235M Estimate
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.46) by 67.39 percent. This is a 63.41 percent increase over losses of $(0.41) per share
Benzinga Newsdesk
PRO
NewAmsterdam Pharma Q2 EPS $(0.15) Beats $(0.46) Estimate, Sales $19.145M Beat $2.235M Estimate
Benzinga Newsdesk
